Rationing in urologic oncology: Lessons from sipuleucel-T for advanced prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 7, 2013, Pages 1079-1084

  Peppercorn, Jeffrey ^a   Armstrong, Andrew ^a   Zaas, David W ^a   George, Daniel ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Castrate resistant prostate cancer; Health policy; Immunologic therapy; Rationing; Sipuleucel T

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTINEOPLASTIC AGENT; CISPLATIN; CYTARABINE; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PACLITAXEL; SIPULEUCEL T;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL THERAPY; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL ETHICS; MEDICAL PRACTICE; ORCHIECTOMY; ORGAN TRANSPLANTATION; PATIENT ADVOCACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATECTOMY; UNITED STATES;

CASTRATE RESISTANT PROSTATE CANCER; HEALTH POLICY; IMMUNOLOGIC THERAPY; RATIONING; SIPULEUCEL-T;

CANCER VACCINES; DRUG APPROVAL; HUMANS; IMMUNOTHERAPY; MALE; MEDICAL ONCOLOGY; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TISSUE EXTRACTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; UROLOGIC NEOPLASMS;

EID: 84884673177     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.12.022     Document Type: Article

References (27)

1. McDavid K., Tucker T.C., Sloggett A., et al. Cancer survival in Kentucky and health insurance coverage. Arch Intern Med 2003, 163:2135-2144.
2. Jagsi R., DeLaney T.F., Donelan K., et al. Real-time rationing of scarce resources: The Northeast Proton Therapy Center experience. J Clin Oncol 2004, 22:2246-2250.
3. Sherman D., Steenhuysen J. U.S. cancer drugs shortage has doctors scrambling. Reuters June 8, 2011.
4. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
5. Jemal A., Siegel R., Xu J., et al. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
6. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
7. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial. Lancet 2010, 376:1147-1154.
8. Beer T.M., Ryan C.W., Venner P.M., et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT Investigators. J Clin Oncol 2007, 25:669-674.
9. Higano C.S., Schellhammer P.F., Small E.J., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115:3670-3679.
10. Small E.J., Fratesi P., Reese D.M., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000, 18:3894-3903.
11. Edwards M. Triage. Lancet 2009, 373:1515.
12. Scribner B.H. Lasker Clinical Medicine Research Award. Medical dilemmas: The old is new. Nat Med 2002, 8:1066-1067.
13. Organ Distribution: Allocation of Deceased Kidneys. In: OPTN/UNOS Board of Directors 2010.
14. Ailworth E. Patients OK as genzyme cleans up drug facility. Boston Globe July 10, 2009.
15. Horwitz S.B. How to make taxol from scratch. Nature 1994, 367:593-594.
16. Randall T. Prostate Cancer Patients Face Yearlong Rationing of Provenge. Bloomberg. Com June 28, 2010.
17. Meropol N.J., Schrag D., Smith T.J., et al. American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 2009, 27:3868-3874.
18. Fojo T., Grady C. How much is life worth: Cetuximab, non-small-cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009, 101:1044-1048.
19. Schnipper L.E., Meropol N.J., Brock D.W. Value and cancer care: Toward an equitable future. Clin Cancer Res 2010, 16:6004-6008.
20. Pearson S.D., Rawlins M.D. Quality, innovation, and value for money: NICE and the British National Health Service. JAMA 2005, 294:2618-2622.
21. Ubel P.A., Hirth R.A., Chernew M.E., et al. What is the price of life and why doesn't it increase at the rate of inflation?. Arch Intern Med 2003, 163:1637-1641.
22. Konski A., Speier W., Hanlon A., et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?. J Clin Oncol 2007, 25:3603-3608.
23. Xie J., Namjoshi M., Wu E.Q., et al. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm 2011, 17:621-643.
24. Grabner M., Onukwugha E., Jain R., et al. Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. J Oncol Pract 2011, 7(3 Suppl):e16s-e24s.
25. Lee C.P., Chertow G.M., Zenios S.A. An empiric estimate of the value of life: Updating the renal dialysis cost-effectiveness standard. Value Health 2009, 12:80-87.
26. Sullivan R., Peppercorn J., Sikora K., et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011, 12:933-980.
27. Peppercorn J.M., Smith T.J., Helft P.R., et al. American Society of Clinical Oncology Statement: Toward Individualized Care for Patients with Advanced Cancer. J Clin Oncol 2011, 29:755-760.